FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileACADIA Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ACAD
ACADIA Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for ACADIA Pharmaceuticals Inc. (ACAD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisACAD
ACAD
ACADIA Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ACAD
  1. Home
  2. Stocks
  3. ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

🇺🇸ACAD•NASDAQ

ACADIA Pharmaceuticals Inc.

🇺🇸ACAD•NASDAQ
Market cap
$3.23B
Sentiment

Your view on ACAD

Mkt Cap
$3.23B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ACADIA Pharmaceuticals Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Catherine E. Owen Adams
Headquarters
12830 El Camino Real, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Catherine E. Owen Adams
Headquarters
12830 El Camino Real, San Diego, CA, US
Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.

ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for ACADIA Pharmaceuticals Inc. from FRC's valuation model, read against the market price. ACAD last traded at $18.67, 8.9× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for ACADIA Pharmaceuticals Inc.. Starting points for ACADIA Pharmaceuticals Inc.: P/E 8.9, EPS $2.10, beta 0.89 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for ACADIA Pharmaceuticals Inc.. ACADIA Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for ACADIA Pharmaceuticals Inc.. Trailing twelve-month EPS for ACADIA Pharmaceuticals Inc. stands at $2.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$31.50

average of 15 firms, last 12 months

 

$31.50

Low $14.50

Median $33.00

High $38.00

 

Analyst Ratings

Buy16 firms, last 12 months
  • Strong Buy0
  • Buy12
  • Hold4
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.27$0.24$0.76$1.05
Low estimate$0.17$0.11$0.56$0.48
High estimate$0.50$0.41$1.04$1.81
No. of analysts1131213
Year-ago EPS$1.601$0.021$2.291—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$362.59M$348.42M$1.28B$1.44B
Low estimate$355.50M$331.97M$1.26B$1.42B
High estimate$371.66M$366.56M$1.29B$1.50B
No. of analysts1231414
Year-ago revenue$283.99M$268.06M$1.07B—
Growth+27.7%+30.0%+19.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 6, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for ACADIA Pharmaceuticals Inc.. ACADIA Pharmaceuticals Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ACAD20 companies · 8 funds
Compare ACAD with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ANROAlto Neuroscience, Inc.Biotechnology$1.1B
  • AVXLAnavex Life Sciences Corp.Biotechnology$76M
  • AXSMAxsome Therapeutics, Inc.Biotechnology$7.2B
  • CTNMContineum Therapeutics, Inc. Class A Common StockBiotechnology$342M
  • LBRXLB Pharmaceuticals Inc Common StockBiotechnology$1.4B
  • MPLTMapLight Therapeutics, Inc.Biotechnology$294M
  • NMRANeumora Therapeutics, Inc. Common StockBiotechnology$69M
  • PRAXPraxis Precision Medicines, Inc.Biotechnology$8.7B

More Biotechnology companies

  • TLX.AXTelix Pharmaceuticals LimitedASX
  • TNGNQTengion, Inc.OTC$4,025
  • TNGXTango Therapeutics, Inc.NASDAQ$4.1B
  • TNXPTonix Pharmaceuticals Holding Corp.NASDAQ$56M
  • TNYATenaya Therapeutics, Inc.NASDAQ$76M
  • TOVXTheriva Biologics, Inc.AMEX$6M
  • TPSTTempest Therapeutics, Inc.NASDAQ$7M
  • TRAWTraws Pharma, Inc.NASDAQ$4M
  • TRAXFirst Tracks Biotherapeutics IncNASDAQ$2.0B
  • TRDAEntrada Therapeutics, Inc.NASDAQ$196M
  • TRP.AXTissue Repair LtdASX
  • TRSBF3SBio Inc.OTC$6.2B

ETFs holding ACADIA Pharmaceuticals Inc.

% of the fund

  • XUU.TOiShares Core S&P U.S. Total Market Index ETF$4.6B in assets
  • IJRiShares Core SP Small-Cap ETF$103.8B in assets0.13%
  • IWMiShares Russell 2000 ETF$76.6B in assets0.08%
  • XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.08%
  • SBIOALPS Medical Breakthroughs ETF$187M in assets2.12%
  • PBEInvesco Biotechnology & Genome ETF$438M in assets1.69%
  • PSCHInvesco S&P SmallCap Health Care ETF$188M in assets1.30%
  • ASCEAllspring SMID Core ETF$418M in assets1.26%

Largest holders first, then the funds most concentrated in ACAD.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold ACADIA Pharmaceuticals Inc., and how their positions are changing. At a $3.23B market value, institutional positions materially move ACADIA Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by ACADIA Pharmaceuticals Inc. executives and directors. Shares of ACADIA Pharmaceuticals Inc. have traded between $13.40 and $26.65 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming ACADIA Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for ACADIA Pharmaceuticals Inc.. Coverage tracks ACADIA Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of ACADIA Pharmaceuticals Inc.

ACAD Analysis
Strong
Past4
Growth5
Health5
Profit4
Value3

News

Latest Market News